This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (16)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

W. H. WOLBERG, M.D.; A. R. CURRERI, M.D.

AMA Arch Surg. 1960;81(2):244-250.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Chemotherapy as an adjunct to surgery has been evaluated both in the experimental animal and clinically by Cole and his co-workers.^3,7,10 The Cancer Chemotherapy National Service Center has sponsored a large-scale clinical evaluation among a group of universities and cancer institutes which are employing a common protocol. The drugs presently under study are mechlorethamine (HN₂), triethylenethiophosphoramide (TSPA), and chlorambucil. These alkylating agents produced an increased incidence in toxicity, leukopenia, and complications when they were administered as adjuncts to surgery.^5,9

5-Fluorouracil has demonstrated clinical usefulness in a number of neoplastic lesions^1,4,8 and consideration should be given to its possible use as an adjunct to surgery. This compound when given on a schedule of 15 mg/kg. daily for five days frequently elicits moderate to marked leukopenia, stomatitis, and diarrhea.^1,4,8 In a preliminary pilot study the above dose given daily for three or four days produced a profound . . . [Full Text PDF of this Article]

Author Affiliations
Madison, Wis.

Cancer Research Hospital, University of Wisconsin, Department of Surgery.

Footnotes
Read at the 17th Annual Meeting of the Central Surgical Association, Chicago, Feb. 19, 1960.

Supported by U.S. Public Health Service Grant No. CY-2859 and Elaine B. Schober Memorial Fund.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?